Giorgi Rossi Paolo, Carretta Elisa, Mangone Lucia, Baracco Susanna, Serraino Diego, Zorzi Manuel
1 Servizio Interaziendale di Epidemiologia AUSL di Reggio Emilia, Italy.
2 Arcispedale S. Maria Nuova, IRCCS, Reggio Emilia, Italy.
J Med Screen. 2018 Mar;25(1):32-39. doi: 10.1177/0969141316686391. Epub 2017 Feb 14.
Objective In Italy, colorectal screening programmes using the faecal immunochemical test from ages 50 to 69 every two years have been in place since 2005. We aimed to measure the incidence of interval cancers in the two years after a negative faecal immunochemical test, and compare this with the pre-screening incidence of colorectal cancer. Methods Using data on colorectal cancers diagnosed in Italy from 2000 to 2008 collected by cancer registries in areas with active screening programmes, we identified cases that occurred within 24 months of negative screening tests. We used the number of tests with a negative result as a denominator, grouped by age and sex. Proportional incidence was calculated for the first and second year after screening. Results Among 579,176 and 226,738 persons with negative test results followed up at 12 and 24 months, respectively, we identified 100 interval cancers in the first year and 70 in the second year. The proportional incidence was 13% (95% confidence interval 10-15) and 23% (95% confidence interval 18-25), respectively. The estimate for the two-year incidence is 18%, which was slightly higher in females (22%; 95% confidence interval 17-26), and for proximal colon (22%; 95% confidence interval 16-28). Conclusion The incidence of interval cancers in the two years after a negative faecal immunochemical test in routine population-based colorectal cancer screening was less than one-fifth of the expected incidence. This is direct evidence that the faecal immunochemical test-based screening programme protocol has high sensitivity for cancers that will become symptomatic.
目的 在意大利,自2005年起实施了面向50至69岁人群、每两年进行一次粪便免疫化学检测的结直肠癌筛查项目。我们旨在测定粪便免疫化学检测结果为阴性后的两年内间期癌的发病率,并将其与结直肠癌筛查前的发病率进行比较。方法 利用活跃筛查项目地区的癌症登记处收集的2000年至2008年意大利结直肠癌诊断数据,我们确定了在筛查检测结果为阴性后的24个月内发生的病例。我们将检测结果为阴性的检测次数作为分母,按年龄和性别进行分组。计算筛查后第一年和第二年的比例发病率。结果 在分别随访12个月和24个月的579,176名和226,738名检测结果为阴性的人群中,我们在第一年发现了100例间期癌,第二年发现了70例。比例发病率分别为13%(95%置信区间10 - 15)和23%(95%置信区间18 - 25)。两年发病率的估计值为18%,女性(22%;95%置信区间17 - 26)和近端结肠(22%;95%置信区间16 - 28)的发病率略高。结论 在基于人群的常规结直肠癌筛查中,粪便免疫化学检测结果为阴性后的两年内间期癌的发病率低于预期发病率的五分之一。这直接证明了基于粪便免疫化学检测的筛查项目方案对将会出现症状的癌症具有高敏感性。